Get started
Author

Mahrou Vahabi

Small cell lung cancer: Novel treatments beyond immunotherapy
2022 · Job-Joris Meijer, Alessandro Leonetti, et al. · Seminars in Cancer Biology · 120
miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells
2019 · Mahrou Vahabi, Claudio Pulito, et al. · Journal of Experimental & Clinical Cancer Research · 102
PDF
PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
2020 · Federica Ganci, Claudio Pulito, et al. · Clinical Cancer Research · 51
PDF
MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies
2021 · Mahrou Vahabi, Giovanni Blandino, et al. · Translational Cancer Research · 48
PDF
Role of exosomes in transferring chemoresistance through modulation of cancer glycolytic cell metabolism
2023 · Mahrou Vahabi, Annalisa Comandatore, et al. · Cytokine & Growth Factor Reviews · 34
Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma
2023 · Mahrou Vahabi, Bilal Dehni, et al. · Cancer and Metastasis Reviews · 29
PDF
Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer
2022 · Silvia Di Agostino, Mahrou Vahabi, et al. · Non-Coding RNA · 20
PDF
Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma
2024 · Daniel S.K. Liu, Jisce R. Puik, et al. · Journal of Experimental & Clinical Cancer Research · 16
PDF
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer
2023 · Mahrou Vahabi, Annalisa Comandatore, et al. · Seminars in Cancer Biology · 15
Extracellular vesicles: Emerging mediators of cell communication in gastrointestinal cancers exhibiting metabolic abnormalities
2023 · Ghazaleh Pourali, Nima Zafari, et al. · Cytokine & Growth Factor Reviews · 10
PDF
Unraveling resistance mechanisms to the novel nucleoside analog RX-3117 in lung cancer: insights into DNA repair, cell cycle dysregulation and targeting PKMYT1 for improved therapy
2025 · Mahrou Vahabi, Geng Xu, et al. · Journal of Experimental & Clinical Cancer Research · 5
PDF
Advances in target drugs and immunotherapy for biliary tract cancer
2024 · Chiara Deiana, Chiara Ricci, et al. · Expert Review of Gastroenterology & Hepatology · 4
The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance
2026 · Benoit Immordino, Mafalda Angelica Rocco, et al. · Drug Resistance Updates · 1
New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma
2025 · Camilla Pecoraro, Daniela Carbone, et al. · Marine Drugs · 1
PDF
Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer
2024 · Mahrou Vahabi, Geng Xu, et al. · Nucleosides Nucleotides & Nucleic Acids · 1
PDF
Extracellular Vesicle-associated AXL Drives Pancreatic Cancer Metastasis and Enables Liquid Biopsy-based Patient Stratification
2026 · Giulia Lencioni, Benoit Immordino, et al. · The Journal of Liquid Biopsy
PDF
Exploiting microRNAs as circulating biomarkers and regulators of key targetable proteins to combat cancer chemoresistance
2026 · Mahrou Vahabi
Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer
2025 · Geng Xu, Camilla Pecoraro, et al. · Cancer Drug Resistance
Supplementary Figure 7 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
2023 · Federica Ganci, Claudio Pulito, et al.
Supplementary Figure 1 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
2023 · Federica Ganci, Claudio Pulito, et al.
Supplementary Figure 2 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
2023 · Federica Ganci, Claudio Pulito, et al.
Supplementary Figure 6 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
2023 · Federica Ganci, Claudio Pulito, et al.
Supplementary Figure 3 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
2023 · Federica Ganci, Claudio Pulito, et al.
Supplementary Figure 4 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
2023 · Federica Ganci, Claudio Pulito, et al.
Supplementary Figure 5 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
2023 · Federica Ganci, Claudio Pulito, et al.
Works count: 51
Citation count: 457
H-index: 10
I10-index: 10
Year
Topic
Type